| Expression pattern: |
UP |
| Associated gene: |
KU heterodimer, KU70, KU80 |
| Associated microRNA: |
- |
| Biological function: |
CircUGGT2 promotes bladder cancer cell migration and invasion, facilitates bladder cancer progression, and promotes cisplatin resistance by enhancing DNA double-strand break repair through the NHEJ pathway. |
| Molecular mechanism: |
CircUGGT2 interacts with the KU heterodimer, promotes recruitment of DNA-PKcs, XRCC4, and other NHEJ repair factors to damaged chromatin, promotes H2AX phosphorylation and gammaH2AX formation, enhances DSB repair, and thereby induces CDDP resistance. |
| Biological pathway or process: |
migration (promotes); invasion (promotes); apoptosis (inhibits); drug resistance (promotes); chemoresistance (promotes); other pathway/process (promotes) |
| Detected method: |
Q
M
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; FISH / smFISH; IF (Immunofluorescence); Nuclear-Cytoplasmic Fractionation; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Transfection; CCK8; Wound Healing Assay; Transwell Assay; Annexin V/PI Flow Cytometry; Western Blot; In Vivo Animal Model; Survival Analysis; Bioinformatics Analysis |
| Clinical significance: |
High circUGGT2 expression is associated with higher clinicopathological stage, muscle-invasive tumors, larger tumor volumes, worse prognosis, and may serve as a potential prognostic marker and therapeutic target. |
| Description: |
CircUGGT2 is upregulated in bladder cancer tissues and cell lines and its high expression is associated with aggressive clinicopathological features and poor survival. Mechanistically, circUGGT2 binds the KU70/KU80 heterodimer and enhances recruitment of NHEJ repair factors to damaged chromatin, promoting DNA repair, gammaH2AX formation, and cisplatin resistance. |
| Confidence score: |
0.8635 |